Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01244191 · ClinicalTrials.gov registry record · Phase 3
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
A Phase 3 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,048
- Enrollment target
NCT01244191 is a Phase 3 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 1,048 participants.
The verdict
NCT01244191, a Phase 3 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,048 participants
- Enrollment target
Study Summary
This study is to determine if the combination regimen of tivantinib with erlotinib will improve overall survival relative to erlotinib alone in subjects with locally advanced or metastatic non-squamous, non-small cell lung cancer who have received 1 or 2 prior systemic anti-cancer therapies.
Interventions
- DRUG Placebo
- DRUG Erlotinib
- DRUG Tivantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,048 participants |
| Start Date | 2011-01-11 |
| Est. Completion | 2012-12-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01244191
The ClinicalTrials.gov registry entry for NCT01244191 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,048 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01244191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01244191 about?
NCT01244191 is a clinical study titled "Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer". This study is to determine if the combination regimen of tivantinib with erlotinib will improve overall survival relative to erlotinib alone in subjects with locally advanced or metastatic non-squamous, non-small cell lung cancer who have received 1 or 2 prior systemic anti-cancer therapies.
What is the current status of trial NCT01244191?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,048 participants. The study started on 2011-01-11. Estimated completion is 2012-12-15.
What interventions are being tested in trial NCT01244191?
The interventions under investigation include: Placebo (DRUG), Erlotinib (DRUG), Tivantinib (DRUG).
Who is sponsoring clinical trial NCT01244191?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.